The new biosimilar offers an additional treatment option for patients with multiple myeloma, bone metastases, and giant cell tumors of the bone.
FDA approval of Emcitate (tiratricol) offers the first targeted therapy for peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 deficiency.
Betzaida Tejada-Vera, from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from all death certificates filed in the 50 states and the District of Columbia ...
Associations included higher prevalence of focal to bilateral tonic-clonic seizures in drug-resistant epilepsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results